Paula Alonso-Frías Publishes Multicentre Study on hUC-PRP for Endometrial Regeneration

Paula Alonso-Frías Publishes Multicentre Study on hUC-PRP for Endometrial Regeneration

October 25, 2026 Dr. Michael Lee – Health Editor Health

Multicentre Trial Evaluates Umbilical Cord Blood Plasma for Endometrial Regeneration

Researchers have published the first-in-human multicentre pilot study evaluating hysteroscopic subendometrial human umbilical cord blood platelet-rich plasma injections for women with refractory Asherman’s syndrome, endometrial atrophy, or thin endometrium, hemostasistoday.com reported. The in-press paper details a novel regenerative approach designed to address a clinical field historically constrained by a lack of gold-standard treatments.

Key Clinical Takeaways:

  • The first-in-human, multicentre pilot study evaluated hUC-PRP injections for refractory Asherman’s syndrome, endometrial atrophy, and thin endometrium.
  • Paula Alonso-Frías, a PhD candidate at the IVI Foundation, co-authored the findings published in Reproductive BioMedicine Online.
  • Evaluations demonstrated improvements in endometrial thickness, endometrial pattern, and neoangiogenesis alongside specific transcriptomic and proteomic changes.

Clinical Outcomes and Biological Mechanisms in the Study

Led by Paula Alonso-Frías, a PhD candidate at the IVI Foundation, the author team investigated both clinical outcomes and the underlying molecular shifts accompanying the treatment. Alongside Alonso-Frías, the study was co-authored by Adolfo Rodríguez-Eguren, Clara Bueno-Fernandez, María Gómez-Álvarez, Marcos Agustina-Hernández, Emilio Francés-Herrero, Mónica Romeu, Carmen Vidal, Lucía de Miguel-Gómez, Amparo Faus, Ana Monzó, Amparo Carrasco, Antonio Parraga-Leo, Patricia Díaz-Gimeno, Leonor Senent, Carmen Lloret-Sos, María Dolores Gómez-Ruiz, Pedro Asensi Cantó, Pilar Solves, Inés Gómez-Seguí, Begoña Laiz-Marro, Antonio Pellicer, and Irene Cervelló Alcaraz. Alonso-Frías expressed pride in the collaborative work on the IVI Foundation’s research initiative, thanking Cervelló Alcaraz for guidance and support.

The pilot study combined clinical, vascular, and transcriptomic endometrial analyses with extensive proteomic and metabolomic characterisation of the injectate. The recent article outlines how hUC-PRP administration associates with measurable gains in endometrial thickness and pattern restoration, alongside active neoangiogenesis. Transcriptomic markers pointed toward enhanced cellular proliferation, angiogenesis, hormone responsiveness, and extracellular matrix remodeling, signaling the activation of a reparative tissue environment. The growth factor-rich composition of human umbilical cord blood platelet-rich plasma provides a consistent biological rationale for further exploration across different endometrial pathologies.

Future Directions in Regenerative Reproductive Medicine

While the multicentre results establish a biological foundation for hUC-PRP therapy, the research team notes that significant work remains to fully map its clinical utility. Patients facing refractory infertility-related endometrial disorders currently have few reliable therapeutic options to restore structural integrity. Additional investigation will determine how these early regenerative signs translate into long-term reproductive success and live birth rates for affected cohorts.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

More on this